# Early phase 1 cancer trials recruiting: 176 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 176 trials in early phase 1 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 cancer trials: 176 rows for $8.80, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 176
- Recruiting or not yet: 176
- Read on: November 19, 2026

## Trials

The 25 newest of 176, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07892300 | Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892300) |
| October 19, 2026 | NCT07879547 | Safety and Diagnostic Efficacy of 177Lu-AF03 in Patients With Solid Tumors | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Malignant Solid Tumors, Neoplasms | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879547) |
| October 13, 2026 | NCT07869823 | Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck | Vanderbilt-Ingram Cancer Center | Early phase 1 | Recruiting | Cutaneous Squamous Cell Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869823) |
| September 10, 2026 | NCT07812259 | Clinical Tolerance of an Intraparotid Injection of Bupivacaine, Combined With Dexamethasone, After Parotidectomy for Benign Tumor | Centre Hospitalier Universitaire de Nīmes | Early phase 1 | Recruiting | Parotid Neoplasm, Bupivacaine, Dexamethasone | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812259) |
| September 3, 2026 | NCT07802756 | Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | Suzhou Immunofoco Biotechnology Co., Ltd | Early phase 1 | Not yet recruiting | Relapsed/Refractory Hematologic Malignancies | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802756) |
| August 27, 2026 | NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | Peking University Cancer Hospital & Institute | Early phase 1 | Not yet recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790939) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 12, 2026 | NCT07761416 | Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention | St. Joseph's Healthcare Hamilton | Early phase 1 | Not yet recruiting | Ovarian Cancer, Bariatric Surgery, Opportunistic Salpingectomy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761416) |
| August 3, 2026 | NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Early phase 1 | Recruiting | HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741565) |
| July 27, 2026 | NCT07727473 | Preoperative Semaglutide Prior to Radical Prostatectomy | Banner Health | Early phase 1 | Not yet recruiting | Prostate Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727473) |
| July 16, 2026 | NCT07707999 | Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Not yet recruiting | Malignant Neoplasm | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707999) |
| July 16, 2026 | NCT07707531 | A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and... | Huashan Hospital | Early phase 1 | Recruiting | Gastric Cancer, Pancreatic Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707531) |
| June 30, 2026 | NCT07674771 | Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed... | University of Texas Southwestern Medical Center | Early phase 1 | Not yet recruiting | Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674771) |
| June 26, 2026 | NCT07671092 | Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | RayzeBio, Inc. | Early phase 1 | Recruiting | Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671092) |
| June 23, 2026 | NCT07662200 | A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy | Ottawa Hospital Research Institute | Early phase 1 | Not yet recruiting | Germ Cell Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662200) |
| June 18, 2026 | NCT07657611 | Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Early phase 1 | Not yet recruiting | Neoplasms, Solid Tumors, Neoplasm Metastasis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657611) |
| June 18, 2026 | NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | Base Therapeutics (Shanghai) Co., Ltd. | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657416) |
| June 18, 2026 | NCT07656103 | QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Early phase 1 | Not yet recruiting | Brain Metastasis, Meningeal Metastasis, Spinal Cord Metastasis | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656103) |
| June 16, 2026 | NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | Ruijin Hospital | Early phase 1 | Recruiting | Pancreatic Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649928) |
| June 10, 2026 | NCT07639970 | Evaluation of \[⁶⁸Ga/¹⁷⁷Lu\]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Breast Cancer, Head and Neck Cancer (H&N), Pancreatic Cancer, Glioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639970) |
| June 5, 2026 | NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | University of California, Irvine | Early phase 1 | Recruiting | Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628634) |
| June 4, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | University of Arizona | Early phase 1 | Recruiting | Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627191) |
| May 27, 2026 | NCT07608848 | First-in-human Diagnostic Imaging Profile of the Theranostic Pair \[68Ga\]Ga-DOTA-STR-17126 and Low Dose \[177Lu\] Lu-DOTA-STR-17126 in... | Integrated Haematology and Oncology Network | Early phase 1 | Recruiting | Metastatic Breast Cancer, Metastatic Prostate Cancer, GRPR-Targeted Molecular Imaging, Theranostic... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608848) |
| May 19, 2026 | NCT07597772 | Preliminary Trial of SNA014 for Pancreatic Cancer | SmartNuclide Biopharma | Early phase 1 | Recruiting | Pancreatic Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597772) |
| May 15, 2026 | NCT07590856 | A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33 | SmartNuclide Biopharma | Early phase 1 | Not yet recruiting | Colorectal Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590856) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| First Affiliated Hospital of Fujian Medical University | 6 |
| M.D. Anderson Cancer Center | 5 |
| Vanderbilt-Ingram Cancer Center | 4 |
| Peking Union Medical College Hospital | 4 |
| Zhejiang University | 3 |
| Jonsson Comprehensive Cancer Center | 3 |
| Ruijin Hospital | 3 |
| Shanghai Juncell Therapeutics | 3 |
| Emory University | 3 |
| FindCure Biosciences (ZhongShan) Co., Ltd. | 3 |
| Dana-Farber Cancer Institute | 3 |
| Mayo Clinic | 3 |
| BioSyngen Pte Ltd | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| Shanghai Changzheng Hospital | 2 |
| Anhui Provincial Hospital | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| University of California, Irvine | 2 |
| Washington University School of Medicine | 2 |
| University of Arizona | 2 |
| University of Alabama at Birmingham | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2 |
| Abramson Cancer Center at Penn Medicine | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Baylor Research Institute | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 82 |
| China | 60 |
| Canada | 4 |
| Australia | 3 |
| France | 2 |
| Greece | 2 |
| New Zealand | 1 |
| South Africa | 1 |
| Netherlands | 1 |
| United Kingdom | 1 |
| Israel | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Grout companies in the United States](https://specstream.ai/data/businesses/grout-companies/united-states)
- [Guatemalan restaurants in the United States](https://specstream.ai/data/businesses/guatemalan-restaurants/united-states)
